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ABSTRACT
Background: Pancreatic ductal adenocarcinoma (PDA) is a highly lethal cancer. Clinicians
commonly refer to surgical therapy as resection with curative intent. However, PDA cure rates
after resection remain unknown and the definition of cure remains vague. We investigated how
patients (the majority undergoing resection), family members, and clinicians understand the
concept of cure, to better inform discussions with patients regarding PDA prognosis.
Methods: In a prospective survey, cohorts were asked to indicate the best definition of cure from
three choices: 5-year survival endpoint (typically used in the literature); a biological endpoint
without biochemical or radiographic signs of disease (similar to the NCI definition); or a
practical endpoint where life span approximates similarly aged patients without PDA. Fleiss’
kappa statistic was calculated to measure inter-rater agreement.
Results: Patients, family members and health care professionals (N=200) agreed that
renormalization of life expectancy was the preferred definition of cure in the context of
pancreatic cancer. Inter-rater agreement was highest for the patient and family member groups
(Fleiss’ Kappa 0.27 and 0.40 respectively. P<0.001), while variability was observed between
health care professionals (Fleiss’ Kappa 0.11, P<0.001).
Conclusions: In all groups surveyed, the probability for a normal life expectancy is the preferred
long-term metric in patients with early-staged pancreatic cancer. Renormalization of life
expectancy appears to be an important therapy goal for PDA patients and it is advisable to
address this topic during clinical discussions.
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INTRODUCTION
Pancreatic cancer is currently the third leading cause of cancer death in the United
States1, and is expected to become second to lung cancer within the next decade. The disease is
highly lethal with an overall 5-year survival of only 9%1-3. Patients with advanced disease have
five-year survival rates of just 3%2,3. Approximately 20% of patients with PDA have localized
and resectable disease at diagnosis and this group has the best long-term outcome. In this
resected subgroup, five-year survival rates are 15-18%4-6. In fact, patients undergoing resection
for PDA are the only ones believed to have a realistic chance for cure.
A cancer cure is the ultimate hope for every patient. Clinicians may occasionally suggest
a possibility of this desired outcome during preoperative discussions. In some cases, clinicians
may even suggest that a cure has been achieved, particularly after a long follow-up interval.
However, to our knowledge, there has never been an attempt to quantify cure rates after PDA
resection. To date, the five-year survival rate has been the gold standard definition for long-term
outcome in this cohort. Importantly, a small number of studies with longer follow-up clearly
indicate that recurrences and cancer-specific mortality occur beyond this 5-year time point6.
Moreover, while conventional clinical survival endpoints (cancer-specific mortality, disease free
survival, etc.)7 are useful for research studies and clinical trials to benchmark progress, they may
have less meaning for patients and their families who are unaccustomed to processing statistical
information.
The NCI provides the following statement on cancer cure 8:
“Cure means that there are no traces of your cancer after treatment and the cancer will never
come back…If you remain in complete remission for 5 years or more, some doctors may say that
you are cured. Still, some cancer cells can remain in your body for many years after treatment.
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These cells may cause the cancer to come back one day. For cancers that return, most do so
within the first 5 years after treatment. But, there is a chance that cancer will come back later.
For this reason, doctors cannot say for sure that you are cured. The most they can say is that
there are no signs of cancer at this time.”
Not only is a cancer cure impossible to determine clinically, but application of this definition
assumes that patients desire, above all else, to have their disease eradicated and for it to never
return. But what if patients die prematurely for other reasons, such as from complications of their
surgery or chemotherapy? Such an outcome is clearly less desirable than a biologic cure. On the
other hand, a ‘healthy’ normal life span may be a more appealing endpoint, even if there remains
radiologic or biochemical evidence of indolent, non-active disease.
In population-based biostatistics, cure is defined as the normalization of the mortality rate
in the affected population back to the same level as in the general population9. Several studies
have looked at this definition in an attempt to estimate cancer cure rates10,11. However, the use of
this definition is still mainly limited to cross-sectional population based studies with minimal use
in the clinical setting. Determining the best survival endpoint and definition of cure has
important implications for surveillance strategies, as well as for discussions between clinicians
and patients. Thus, we sought to determine a practical definition of cure with objective,
quantifiable end-points, consistent with patients’ and providers’ perceptions of the endpoint and
their goals of treatment.
MATERIALS AND METHODS
A prospective, questionnaire-based study was designed to assess stakeholder perspectives on
curative therapy as well as their desired goals of treatment (Supplementary Figure 1). The study
was performed between November 2016 and May 2017. Participants were approached during the
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annual pancreatic cancer and related diseases symposium (November 2016, Thomas Jefferson
University, Philadelphia, PA) and during regular outpatient clinic visits. Surveyed individuals
included patients, their family members, and clinicians/cancer researchers (i.e, senior surgeons,
oncologists, clinical researchers, and translational pancreatic cancer researchers). Most patients
included in the study had previously undergone curative intent pancreatic resection; some had
already experienced a cancer recurrence. Gender, age and study group (1: Patients, 2: Family
Members and 3: Clinicians/Clinical pancreatic cancer researchers) were recorded. For
individuals in group 1 (patients), participants were also asked to indicate whether a
pancreatectomy was performed. All participants were asked to review three possible scenarios,
and select the one which most closely met their definition of a pancreatic cancer cure (See
Supplementary Figure 1):
A. Surviving for 5 years (i.e., the literature benchmark).
B. Having normal laboratory and imaging test results for the rest of your life (i.e., scientific
definition, an approximation of the NCI statement above).
C. Living a normal life span, similar to an age-matched person without pancreatic cancer
(i.e., a practical definition).
Participants were also asked to rate these statements according to how useful each of the metrics
were in their view, as compared to the other choices (from the most informative endpoint to the
least informative). Between-group analysis was then performed using Wilcoxon’s ranked test.
Within-group determination of internal agreement was performed using R12 (R version 3.3.2,
2016, The R foundation for statistical computing) with the raters package13 for Fleiss’ Kappa
test. P values ≤ 0.05 were considered as statistically significant. Questionnaires were indexed by
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a serial number, and no patient identifiable data were recorded. The study was approved by the
Thomas Jefferson University Institutional Review Board.
RESULTS
Defining pancreatic cancer cure
A total of 350 questionnaires were prepared and assigned form identifiers. Of these 200
questionnaires were returned for analysis (57%). Cohort characteristics and question response
rates are provided in Tables 1-2. Average question response rates were >95% across each
subgroup. Normal life expectancy was the preferred definition for pancreatic cancer cure
(chosen by 67% of the participants, Figure 1A, P<0.01) in the whole cohort, as well as for each
questioned sub-group (Figure 1B). Interestingly, while the five year survival endpoint is the
standard survival endpoint used in the literature, respondents considered this definition to be the
least meaningful out of the provided choices. Only 5% of respondents preferred this metric. The
response profile was only slightly different in the researcher/clinician subgroup compared to
patient and family member subgroups (Figure 1B, P=0.1 and P=0.025, Fisher’s exact test),
although overall trends were similar.
The questionnaire’s second question asked for patients to rank the three possible
definitions based on their subjective informative value. Consistent with the previous question,
normal life expectancy was selected as the most informative metric (ranked as most important by
70% of the participants, P<0.01, Figure 2A), as well as in subgroup analyses (Figure 2B-D). A
high level of inter-group agreement was found in both the patient and patient family member
groups (k=0.25 and k=0.40, respectively, P<0.01). In contrast, the internal agreement levels in
the researcher/clinician subgroup were lower (k=0.09, P<0.01). Thus, the most knowledgeable
individuals had the greatest disagreement.

6

DISCUSSION
Cure is the desired treatment goal of early, or localized, cancer. This principal is even
conveyed in our own Sidney Kimmel Cancer Center’s motto: “Until every cancer is cured.”14. It
therefore seems reasonable to design studies that attempt to capture this important metric,
particularly since it is acknowledged by patients, family members, and clinicians, during
discussions of prognosis. Unfortunately, the biologic definition offered by the NCI (“that there
are no traces of your cancer after treatment and the cancer will never come back.”) cannot be
definitively tracked using currently available cancer surveillance technologies.
Clear, compassionate communication of treatment goals, treatment chances and expected
survival is a challenge, further complicated but a multitude of different survival metrics and
conflicting viewpoint and perceptions. In this study, we offer an alternative definition that can
potentially be quantified and tracked. Moreover, the proposed definition is consistent with the
endpoints desired by the principal stakeholders, including patients, family members, and health
care professionals. Individuals completing the study survey considered three possible definitions
of PDA cure: the standard published outcome metric (5-year survival), a biologic metric similar
in intent to a scientific definition proposed by the NCI (i.e., any detectable trace of disease), and
a practical definition (where life span is renormalized). Each of these definitions has associated
advantages and disadvantages for use as a metric (Table 3). For instance, the five-year survival
milestone is frequently used in the surgical oncology literature as a primary outcome measure4
and is simple to measure. However, the endpoint ignores the fact that late recurrences occur.
Strikingly, the present study revealed that this oft quoted cancer survival endpoint was the least
meaningful out of the survey options offered to study participants. The second definition
considers biologic aspects of cure, and fits best with the NCI definition. However, there is no an
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available test that can definitively rule out the presence of microscopic and sub-clinical PDA,
diminishing its practical utility. The definition is purely conceptual. In the real world, PDA
recurrences are detected using imaging studies and serum tumor markers with sensitivities
around 90%15-17. Assays that test for circulating tumor cells (CTC) 18 have even lower
sensitivities (47-68%) 19,20. Additionally, in other diseases like breast cancer, patients frequently
harbor sub-clinical bone marrow metastases for decades 21-24 without any impact on quality of
life or longevity. This finding suggests that a biologic definition would not be practically
relevant for all patients, especially elderly individuals with other comorbidities. The third
definition has been under-utilized in the cancer literature, but is recommended by the European
Conference on Survivors and Chronic Cancer 25. A determination of ‘normal life expectancy’
can be extracted from general population statistical life tables (for example, life tables from the
Social Security Administration). In fact, all stakeholders in the present study highlighted
renormalization of life expectancy as the preferred definition of PDA cure. From a practical
standpoint, a patient living a normal life span would be considered to be cured by most
stakeholders, even if a test were able to detect subclinical and microscopic disease. While
biologically speaking, the patient in this case would not have been considered as cured, in terms
of cancer treatment goals, most stakeholders in our study preferred that endpoint to the
standardly used endpoint of 5 years of cancer free survivorship.
The manner in which prognosis is conveyed to patients and family members can have
major emotional and social consequences. For instance, the term ”cancer survivorship” is a
stressful reminder for some patients that a threat of recurrence looms26. For others, ‘survivorship’
offers a sense of personal growth and achievement. Terms such as ‘cured’, ‘healed’, and
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remission are more optimistic25, but their intended meaning can be misinterpreted. Indeed, this
study reveals the range of possible interpretations of “cure” in the context of pancreatic cancer.
For PDA, the actual cure rate has never been effectively quantified. Even “early” PDA
lesions (< 2 cm invasive component) have a tendency to spread and recur more frequently than
other similarly sized cancer types 27. Long-term survival studies reveal that patients with
resected PDA reach the 5-year time point roughly 20% of the time 6,28-30; thus, actual cure rates
must be lower than this number. Studies with longer follow-up intervals report that PDA
recurrences occur more than 10 years after resection 6. In fact, conditional survival analyses
show that patients who survive five years after resection still have an excess mortality rate
compared to the general population 31.
Limiting and biasing factors
Several biasing factors in our study limit the interpretation and generalization of the
results. First, this is a single center study. In addition, the vast majority of patient participants
underwent a pancreatic resection (>92%). Most of the patient participants had relatively early
and surgically managed pancreatic tumors at presentation. Therefore, perspectives of patients
who presented with advanced or metastatic disease are not well represented in this survey. While
we have tried to minimize misinformation bias by verbally explaining each of the proposed
definitions during the survey, it is possible that some of the patients misunderstood the questions
or believed some definitions to be inclusive of the other ones. The cross-sectional design of our
study at a single time point also does not consider individual shifts in perspective or opinion over
time. Also, we do not evaluate perceptions of cure for other tumor types. Finally, none of these
definitions precisely and accurately describe the scientific definition of cure. Rather, they
describe patients’ perceptions of cure with respect to their own conditions.
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CONCLUSIONS
Patient-Clinician communication regarding pancreatic cancer cure is complex and prone
to misperception regarding the informative value of different survival statistics. A normal life
expectancy was the most important long-term outcome metric according to patients with earlystaged pancreatic cancer. Clinicians should be mindful in discussion of prognosis that actual
PDA cure rates have not been rigorously determined and remain unknown. Further, the meaning
of cure may not be fully understood by patients and family members. Importantly, the preferred
definition identified in this study - renormalization of anticipated life expectancy – is actually
estimable. This outcome can be calculated through comparisons of PDA survival data and data
from actuarial life tables of age-matched individuals in the general population. Based on these
results, we submit that this new outcome metric (i.e., renormalization of life expectancy) should
be determined for PDA patients, and serve as a new benchmark for scientific progress, with the
ultimate research goal to improve cure rates. Ongoing work in this area by our group is intended
to meet this objective.
Compliance with ethical standards
Conflict of interest: The authors declare that they have no conflicts of interest.
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Table 1
Participant Demographics (N=200)
Age

%Male

(Years)

Pancreatic Resection

Patients (N=93)

65.5 ± 1.2

61%

Family members (N=53)

55.4 ± 2.3

27%

Researchers/Clinicians (N=52)

36.8 ± 1.5

33%

27

0%

Other (N=2)

% Curative-intent

Table 1. Participant demographics (Mean ± Std.Er).
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92.3%

Table 2
Item#1*

Item#2*

Best Cure Definition

Perceived Informative Value

Patients (N=93)

93 (100%)

87 (94%)

Family members (N=53)

49 (92%)

52 (98%)

Researchers/Clinicians (N=52)

52 (100%)

52 (100%)

Other (N=2)

1 (50%)

1 (50%)

Missing Data

5

8

Total

200

200

Table 2. Questionnaire item completion rates (in parenthesis, relative item completion rates in
percentages). * See Supplementary Figure 1.
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Endpoint Definition

Advantages of use

Limitations of use

• Easy to measure and interpret in

• Uninformative for pathologies

Category
Standard

Surviving for 5

reported

years.

clinical studies
• Easy to compare across various

endpoint

groups and cancers.
• Requires a defined short follow
up period
Biologic

Having normal

definition

laboratory and
imaging test results
for the rest of your

with high survival rate
• Generalized and not patient
specific
• Does not capture dormant
disease or delayed recurrences

• Easy to comprehend by nonhealth professionals.
• Closest measurable scientific
endpoint for ‘cure’

• Requires very long term followup
• Over-interprets dormant and
clinically irrelevant disease
• Does not necessarily correlate

life.

with survival
• Difficult to compare across
various groups and cancers.

Practical

Living a normal life • Patient specific

definition

expectancy, similar
to a person without
pancreatic cancer

• Easy to comprehend by nonhealth professionals.
• Requires a defined follow up
period (varies between patients).
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• Allows for existence of active or
dormant disease
• Complicate clinical study design
(requires individual age-adjusted
follow-up durations for patients)

• Easy to compare across various
groups and cancers.

Table 3. Comparison of various survival endpoints with possible advantages and limitations of
use.
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Figure Legends
Figure 1. (A) Participants’ answer distribution for definition of endpoint of cure of pancreatic
cancer (P<0.01, χ2 test). (B) Sub-population comparison of participants’ answer distribution for
definition of endpoint of cure of pancreatic cancer (χ2 test).
Figure 2. Overall and Sub-population comparison of participants’ ranking of three proposed
long-term endpoint metrics for their informative value in pancreatic cancer (Fleiss’ kappa
analysis).
Supplementary Figure 1. Participant Questionnaire
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Figure 1A

Figure 1B
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Figure 2A
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Figure 2B
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Figure 2C
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Figure 2D
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